Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC)

Autores: Graybill, W.; Mirza, M.; González Martín, Antonio; O'Malley, D.; Gaba, L.; Yap, O. W. S.; Guerra, E.; Rose, P. G.; Baurain, J.; Ghamande, S.; Denys, H.; Prendergast, E.; Pisano, C.; Follana, P.; Braicu, E. I.; Calvert, P. M.; Korach, J.; Li, Y.; Gupta, D.; Monk, B. J.